The director's same-day exercise-and-sell is a routine cashless option monetization, not a conviction sale. CSO Hansen's small $36K sale is negligible. No insider buying to offset the selling. Monitor next 10-Q for any insider accumulation or larger C-suite sales that would signal a change in conviction.
Price Chart
Executive Summary
Nurix Therapeutics director Julia P. Gregory executed a same-day derivative exercise and open-market sale of 22,583 shares for $529K, while CSO Gwenn Hansen sold 1,500 shares for $36K. The director's sale follows the company's massive Q3 earnings beat (revenue $673.1M vs $7.9M YoY) and Roche collaboration milestone, but the insider selling is modest relative to the company's market cap and likely reflects routine portfolio diversification after a significant stock price run-up.
Key Financial Metrics
Key Facts
- Director Julia P. Gregory exercised 22,583 derivative shares at $1.86 and immediately sold them at $23.40 for $529K in open-market proceeds
- CSO Gwenn Hansen sold 1,500 shares at $25.00 for $36K on 2026-10-15
- Total insider selling of $565K represents approximately 0.17% of market cap (based on $326M market cap)
- Selling occurred 1-2 days after Q3 2026 earnings release showing $673.1M revenue and $4.73 diluted EPS, massively beating consensus
- Director Gregory's sale was a same-day exercise-and-sell, a common pattern for option monetization with no net directional signal
Financial Impact
Total insider selling of $565K, or ~0.17% of market cap — trivial relative to company size
Risk Factors
- No insider buying despite massive earnings beat and cash position of $1.1B
- Director Gregory's sale could signal personal diversification after stock appreciation, but is not a bearish signal on fundamentals
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-NRIX-1792098056307 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | Insider Cluster | $24.42 | awaiting T+20 | — | $25.55 (+4.63%) |
Oct 14, 2026 12d ago | 144 | $24.95 | awaiting T+20 | — | $25.55 (+2.40%) |
Oct 13, 2026 14d ago | 8-K | $22.13 | awaiting T+20 | — | $25.55 (+15.45%) |
Oct 5, 2026 22d ago | Press Release | $22.88 | awaiting T+20 | — | $25.55 (+11.67%) |
Sep 23, 2026 4w ago | SC 13G | $23.65 $25.51 | ▲ +7.86% | ▲ +8.28% | $25.55 (+8.03%) |
Sep 2, 2026 7w ago | Insider Cluster | $25.32 $22.99 | ▼ −9.20% | ▼ −8.01% | $25.55 (+0.91%) |
Aug 5, 2026 11w ago | Insider Cluster | $25.22 | awaiting T+20 | — | $25.55 (+1.31%) |
Aug 5, 2026 11w ago | Insider Cluster | $25.12 | awaiting T+20 | — | $25.55 (+1.71%) |
Aug 4, 2026 11w ago | Insider Cluster | $25.12 | awaiting T+20 | — | $25.55 (+1.71%) |
Aug 3, 2026 12w ago | Insider Cluster | $24.69 | awaiting T+20 | — | $25.55 (+3.48%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers